BR112023002559A2 - Preparação de combinação para tratar diabetes tipo 2 - Google Patents

Preparação de combinação para tratar diabetes tipo 2

Info

Publication number
BR112023002559A2
BR112023002559A2 BR112023002559A BR112023002559A BR112023002559A2 BR 112023002559 A2 BR112023002559 A2 BR 112023002559A2 BR 112023002559 A BR112023002559 A BR 112023002559A BR 112023002559 A BR112023002559 A BR 112023002559A BR 112023002559 A2 BR112023002559 A2 BR 112023002559A2
Authority
BR
Brazil
Prior art keywords
diabetes
combination preparation
type
formulation
pharmaceutically acceptable
Prior art date
Application number
BR112023002559A
Other languages
English (en)
Inventor
Soon Ahn Jae
Il Yun Duck
Min Kim Dong
Lee Sun
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Publication of BR112023002559A2 publication Critical patent/BR112023002559A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

PREPARAÇÃO DE COMBINAÇÃO PARA TRATAR DIABETES TIPO 2. A presente invenção refere-se a uma formulação de compósito para tratar de forma eficaz diabetes mellitus tipo 2 e, mais especificamente, provê uma formulação de compósito compreendendo: uma primeira camada incluindo metformina ou um sal farmaceuticamente aceitável da mesma, uma dispersão aquosa de acetato de polivinila e um excipiente à base de celulose; e uma segunda camada incluindo gemigliptina ou um sal farmaceuticamente aceitável e um excipiente, em que a formulação é um comprimido de tamanho reduzido projetado para melhorar a adesão à medicação, bem como a regulação da glicose em pacientes com diabetes mellitus tipo 2.
BR112023002559A 2020-08-14 2020-08-14 Preparação de combinação para tratar diabetes tipo 2 BR112023002559A2 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/KR2020/010841 WO2022034944A1 (ko) 2020-08-14 2020-08-14 제2형 당뇨병 치료용 복합제제

Publications (1)

Publication Number Publication Date
BR112023002559A2 true BR112023002559A2 (pt) 2023-03-14

Family

ID=80247912

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023002559A BR112023002559A2 (pt) 2020-08-14 2020-08-14 Preparação de combinação para tratar diabetes tipo 2

Country Status (6)

Country Link
BR (1) BR112023002559A2 (pt)
CL (1) CL2023000415A1 (pt)
CO (1) CO2023002829A2 (pt)
MX (1) MX2023001785A (pt)
PE (1) PE20231638A1 (pt)
WO (1) WO2022034944A1 (pt)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8551524B2 (en) * 2008-03-14 2013-10-08 Iycus, Llc Anti-diabetic combinations
WO2012049566A1 (en) * 2010-10-14 2012-04-19 Japan Tobacco Inc. Combination therapy for use in treating diabetes
KR20130136718A (ko) * 2012-06-05 2013-12-13 한미약품 주식회사 메트포르민 서방성 장용제제 및 이의 제조방법
TWI606848B (zh) * 2012-10-08 2017-12-01 Ｌｇ生命科學股份有限公司 包含格米列汀與美氟明的組合藥物及其製備方法
KR20180002460A (ko) * 2016-06-29 2018-01-08 주식회사 엘지화학 제2형 당뇨병 및 당뇨성 이상지질혈증 치료용 조성물, 키트 및 병용 요법
KR102633770B1 (ko) * 2019-05-24 2024-02-02 주식회사 엘지화학 제2형 당뇨병 치료용 복합제제

Also Published As

Publication number Publication date
CO2023002829A2 (es) 2023-03-27
MX2023001785A (es) 2023-03-10
CL2023000415A1 (es) 2023-10-13
WO2022034944A1 (ko) 2022-02-17
PE20231638A1 (es) 2023-10-16

Similar Documents

Publication Publication Date Title
BR112013024973A2 (pt) prevenção de hipoglicemia em pacientes com diabetes mellitus do tipo 2
JP2018533589A5 (pt)
PE20142319A1 (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero
BR112013019744A2 (pt) prevenção de hipoglicemia em pacientes com diabetes mellitus tipo 2
BR112018016001A2 (pt) composição farmacêutica, métodos de tratamento e usos da mesma
BR112013010021A2 (pt) combinações farmacêuticas para o tratamento de distúrbios metabólicos.
BR112015029918A2 (pt) uso de alta dose de pridopidina para tratar a doença de huntington
BR112016027469A2 (pt) composição para tratamento de diabetes que compreende conjugado de análogo de insulina de ação lenta e conjugado de peptídeo insulinotrópico de ação lenta
BR112013004756B1 (pt) uso de ave0010 para a fabricação de um medicamento para o tratamento da diabetes melito tipo 2
JP2014533680A5 (pt)
NZ710575A (en) Pharmaceutical compositions for the treatment of diabetes mellitus
JP2014515408A5 (pt)
BR112014027884A2 (pt) combinações farmacêuticas para tratamento de distúrbios metabólicos
BR112015007360A2 (pt) composição farmacêutica, e, método para a preparação de uma droga de combinação
BRPI0804623B8 (pt) uso de albumina humana terapêutica para a preparação de um fármaco para o tratamento de pacientes sofrendo de distúrbios cognitivos
BR112015004012A2 (pt) combinações de inibidores de sglt 2 e fármacos anti-hipertensivos
BR112012026005A2 (pt) composições e métodos para tratar diabetes do tipo ii e distúrbios relacionados
BR112023002559A2 (pt) Preparação de combinação para tratar diabetes tipo 2
BR112014004339A2 (pt) suspensão oral
Mishra et al. Effect of Tinospora cordifolia as an add-on therapy on the blood glucose levels of patients with Type 2 diabetes.
BR112017022478A2 (pt) composição farmacêutica de liberação sustentada que contém rivastigmina
BR112018068155A2 (pt) composição farmacêutica de liberação prolongada que compreende cisteamina ou sais da mesma
ECSP23015569A (es) Formulación compuesta para tratamiento de diabetes mellitus tipo 2
JP2011105610A5 (pt)
TR201004720T1 (tr) Majör depresif bozukluğun tedavisi için o-desmetil venlafaksin